In this context, Chai et al. [114] evaluated the therapeutic efficacy of Folate-grafted PEI600-CyD (H1)-based plasmid AIM2 (pAIM2) in renal cancer carcinoma (RCC), a type of tumor where AIM2 expression was significantly decreased. This evidence concerns the gene AIM2 and neoplasm.